Why the study?
Does combined acetylsalicylic acid and dipyridamole prevent occlusion of aortocoronary venous bypass grafts in patients receiving at least three grafts?
Does combined acetylsalicylic acid and dipyridamole prevent occlusion of aortocoronary venous bypass grafts in patients receiving at least three grafts?
Combined dipyridamole and acetylsalicylic acid did not improve 3-month angiographic graft patency compared to placebo in patients undergoing coronary artery bypass grafting.
No benefit of dipyridamole-acetylsalicylic acid on CABG graft patency; challenges additive antiplatelet assumptions and supports alternative regimen trials.
Patients scheduled to receive at least three aortocoronary venous bypass grafts were randomized to active medication or to placebo. The former were given dipyridamole (DP) preoperatively and acetylsalicylic acid (ASA) was added after the operation. For the next 3 months they received DP 75 mg and ASA 325 mg thrice daily. The placebo regimen was identical and the study was conducted with double-blind technique. One patient in each group died. DP-ASA was discontinued in six patients because of gastrointestinal side effects (bleeding peptic ulcer in 2 cases). Angiography after 3 months revealed the patency rate of individual grafts to be 68% in the DP-ASA group and 77% in the placebo group. DP-ASA therefore did not prevent occlusion of aortocoronary venous bypass grafts.
No takes yet. Share an insight, caveat, or question.
Thaulow et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: